Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more
May 09, 2017 edition of the weekly JAMA Editors’ Summary
JAMA Editor’s Summary
Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more
May 09, 2017 edition of the weekly JAMA Editors' Summary
May 9, 2017
Follow JAMA Editor’s Summary on social!
You may also like
The Latest Health Podcasts. Delivered to Your Inbox.
Join Our NewsletterWe gratefully acknowledge the many organizations that have generously supported our podcasts and platform.
Network Sponsors and Advertisers
Event and Media Partners
